Basiliximab( —— )

Catalog No. M36560 CAS No. 179045-86-4

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Basiliximab
Note

Research use only, not for human use.
Brief Description

Basiliximab (CHI 621) is a chimeric mouse/human IgG1 monoclonal recombinant antibody targeting the interleukin-2 receptor, demonstrating potent immunosuppressive activity for use in kidney transplantation studies.
Description

Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation.
In Vitro

Basiliximab specifically inhibits T lymphocyte proliferation by binding to the IL-2Rα.Basiliximab binds only to activated lymphocytes and macrophages/monocytes. Basiliximab does not affect resting T lymphocytes that do not express IL-2Rα.
In Vivo

Basiliximab (CHI 621) (0.07 mg/rat; i.v.; once) decreases total placental natural killer cells in reduced uterine perfusion pressure (RUPP) rats.Animal Model:Timed-pregnant Sprague Dawley (SD) rats, reduced uterine perfusion pressure (RUPP) rat model of placental ischemia Dosage:0.07 mg/rat Administration:IV infusion, once Result:Decreased total placental natural killer cells. Had no effect to lower MAP or improve pup weight and placental weight.
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Interleukin
Research Area

——
Indication

——

1. McKeage K, et al. Basiliximab: a review of its use as induction therapy in renal transplantation. BioDrugs. 2010 Feb 1;24(1):55-76.?

Calculator

molnova catalog